| Title: |
ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone |
| Authors: |
Margaret C. Costanzo; Dominic Paquin-Proulx; Alexandra Schuetz; Siriwat Akapirat; Zhanna Shubin; Dohoon Kim; Lindsay Wieczorek; Victoria R. Polonis; Hung V. Trinh; Mangala Rao; Hanna Anenia; Michael D. Barrera; Jacob Boeckelman; Barbara Nails; Pallavi Thapa; Michelle Zemil; Carlo Sacdalan; Eugene Kroon; Boot Kaewboon; Somporn Tipsuk; Surat Jongrakthaitae; Sanjay Gurunathan; Faruk Sinangil; Jerome H. Kim; Merlin L. Robb; Julie A. Ake; Robert J. O’Connell; Punnee Pitisutthithum; Sorachai Nitayaphan; Suwat Chariyalertsak; Michael A. Eller; Nittaya Phanuphak; Sandhya Vasan; the RV; RV328 study groups |
| Source: |
JCI Insight, Vol 8, Iss 9 (2023) |
| Publisher Information: |
American Society for Clinical investigation, 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Medicine |
| Subject Terms: |
AIDS/HIV; Medicine |
| Description: |
The RV144 phase III vaccine trial demonstrated that ALVAC-HIV and AIDSVAX B/E administration over 6 months resulted in 31% efficacy in preventing HIV acquisition, while administration of AIDSVAX B/E alone in both VAX003 and VAX004 studies failed to show efficacy. In this study, we aimed to understand the impact of ALVAC-HIV on the development of cellular, humoral, and functional immune responses compared to the administration of AIDSVAX B/E alone. ALVAC-HIV in combination with 3 doses of AIDSVAX B/E significantly increased CD4+ HIV-specific T cell responses, polyfunctionality, and proliferation compared with 3 doses of AIDSVAX B/E alone. Additionally, Env-specific plasmablasts and A244-specific memory B cells were identified with a significantly higher magnitude in the group that received ALVAC-HIV. Subsequently, data revealed increased magnitude of plasma IgG binding to and avidity for HIV Env in participants who received ALVAC-HIV compared with 3 doses of AIDSVAX B/E alone. Lastly, levels of the Fc-mediated effector functions antibody-dependent cellular cytotoxicity, NK cell activation, and trogocytosis were significantly increased in participants who received ALVAC-HIV compared with those receiving AIDSVAX B/E alone. Taken together, these results suggest that ALVAC-HIV plays an essential role in developing cellular and humoral immune responses to protein-boosted regimens relative to protein alone. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2379-3708 |
| Relation: |
https://doaj.org/toc/2379-3708 |
| DOI: |
10.1172/jci.insight.167664 |
| Access URL: |
https://doaj.org/article/54ea0fbbfd224eb79d9efe0dfded1c6a |
| Accession Number: |
edsdoj.54ea0fbbfd224eb79d9efe0dfded1c6a |
| Database: |
Directory of Open Access Journals |